High Frequency of Smell and Taste Dysfunction in Health Care Professionals With COVID-19 Working in Allergy Departments

Antolín Amérigo D1,*, Cubero JL2,*, Colás C2, Alobid I3,**, Mullol J4,**, Valero A5,***

1Allergy Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCS), Madrid, Spain
2Allergy Department, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain
3Rhinology and Skull Base Unit, Department of Otorhinolaryngology, Hospital Clinic, Universidad de Barcelona. IDIBAPS, CIBERES, Barcelona, Spain
4Rhinology Unit & Smell Clinic, Department of Otorhinolaryngology, Hospital Clinic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBER of Respiratory Diseases (CIBERES). Barcelona, Catalonia, Spain
5Department of Pneumology and Allergy, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERES, Instituto de Salud Carlos III, Spain
*These authors contributed equally as first authors.
**These authors contributed equally with senior responsibilities.

Abstract

Background: Since the early stages of the novel coronavirus 2019 (SARS-CoV-2) outbreak, smell and/or taste dysfunction (STD) has been reported in 5% to 88% of COVID-19 patients.

Objective: We aimed to assess STD in health care professionals (HCPs), mainly allergists, affected by COVID-19. We carried out a survey to evaluate the association between STD and its severity and demographic characteristics, symptoms, comorbidities, and hospital admission.

Methods: We designed a 15-item questionnaire comprising various sections, as follows: demographics, diagnostic characteristics, STD patterns, medication use, and comorbidities. The questionnaire was developed using Google forms. It was distributed to members of the Spanish Society of Allergology and Clinical Immunology (SEAIC) and sent via social media to be completed by HCPs with COVID-19.

Results: The survey was completed by HCPs (n=234), of whom 73,5% were female. STD was detected in 74,4% of respondents, of whom 95,6% reported moderate-severe impairment. Mean time until recovery of taste dysfunction was 21.6±24.0 days in HCPs aged ≤55 years and 33.6±26.2 days in those aged >55 years (P=.019). Analysis stratified by severity of STD showed that more than a half of COVID-19 patients presented severe loss of smell. Older age (>55 years) was associated with fever, anorexia, lower frequency of headache, and longer persistence of taste dysfunction.

Conclusion: STD is a common symptom in COVID-19, even as a unique or preceding symptom. HCPs who reported smell dysfunction were younger than those not affected with STD. Taste dysfunction may imply more systemic involvement in COVID-19–positive HCPs.

Key words: Smell dysfunction. Hyposmia. Anosmia. Taste dysfunction. Ageusia. Hypogeusia. SARS-CoV-2. COVID-19.

Resumen

Antecedentes: Desde el inicio de la pandemia por el nuevo coronavirus SARS-CoV-2, la afectación del sentido del olfato y del gusto se ha descrito entre el 5% y 88% de la población afecta por COVID-19.

Objetivo: Evaluar la alteración del gusto y del olfato en profesionales sanitarios afectados por COVID-19, en relación a parámetros de gravedad, características demográficas, síntomas, comorbididades e ingreso hospitalario.

Métodos: Se diseñó un cuestionario de 15 elementos, con las siguientes secciones: demografía, características diagnósticas, patrones de alteración del olfato y del gusto, uso de medicación y efectos adversos asociados y comorbididades. Dicho cuestionario fue difundido por las redes sociales de la Sociedad Española de Alergología e Inmunología Clínica, dirigido específicamente a profesionales sanitarios.

Resultados: 234 profesionales completaron la encuesta (73,5% mujeres). El 76,5% de los encuestados era ≤55 años. Hubo afectación del olfato y/o gusto en el 74,4% de los encuestados. La persistencia media de alteración del gusto fue 21,6±24,0 días en ≤55 años y de 33,6±26,2 días en >55 años (P=.019). Ser mayor de 55 años se asociaba estadísticamente con fiebre, anorexia, menor cefalea y mayor persistencia de alteración del gusto.

Conclusión: Los profesionales sanitarios que declararon haber padecido SD eran más jóvenes que los que no presentaron STD. La afectación del olfato y/o del gusto es un síntoma común entre los profesionales sanitarios con COVID-19 y puede ser patente en fases iniciales o como único síntoma en pacientes ≤55 años. La afectación del gusto puede implicar más síntomas sistémicos.

Palabras clave: Afectación del olfato. Hiposmia. Anosmia. Afectación del gusto. Ageusia. Hipogeusia. SARS-CoV-2. COVID-19.
Introduction

In the past 20 years, there have been 3 coronavirus outbreaks: the severe acute respiratory syndrome (SARS) outbreak in 2002, the Middle East respiratory syndrome (MERS) outbreak in 2012, and the coronavirus disease 2019 (COVID-19) pandemic in 2020. In December 2019, the first human cases of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thought to have originated from a bat, were identified in Wuhan, China. Since then, the COVID-19 pandemic has spread rapidly all over the world, affecting over 71 million people and causing over 1 million deaths in 191 countries (probably more if infected people who did not undergo appropriate diagnostic testing are included) [1-3].

The main symptoms of COVID-19 are general malaise, fever, cough, and shortness of breath. Other symptoms include muscle and joint pain, sore throat, headache, nausea or vomiting, diarrhea, and nasal symptoms, especially smell dysfunction (SD) and taste dysfunction (TD) [3]. Since the early stages of COVID-19, when reports of smell and/or taste dysfunction (STD) were scarce, a growing number of studies, with important differences in methodology between them, have reported a wide range of STD (5% to 98%) in COVID-19 patients [2-5].

Perception of odor comprises orthonasal smell, which is the result of sniffing (eg, food aroma), and retronasal smell, which is located within the oropharynx and is caused by airflow via the nasopharynx during eating or drinking. Flavor involves the combination of gustatory and olfactory perceptions and interacts with other sensory modalities, such as trigeminal perception, sight, and hearing [6]. The gustatory system (transmitted via the glossopharyngeal, facial, and vagal nerves) only recognizes basic tastes (sweet, sour, salty, bitter, and umami/glutamate).

SD affects almost 20% of the general population [7]. The main causes of persistent loss of smell are viral infections (including common cold and COVID-19), acute and chronic sinonasal inflammation, and brain injury. The other causes that should be investigated include neurodegenerative diseases, brain tumors, and congenital conditions. There is no significant association between SD and smoking.

Interestingly, many of the viruses affecting the upper aerodigestive tract (eg, rhinovirus, influenza A, parainfluenza, herpesvirus, poliovirus, rabies virus, adenovirus, Epstein-Barr virus, Japanese encephalitis virus, and some coronaviruses) could use the olfactory nerve as a route into the central nervous system, potentially causing SD, mostly through an inflammatory reaction affecting the nasal mucosa [2,8,9]. Mouse models of SARS-CoV demonstrated transneuronal penetration through the olfactory bulb [8,10]. Involvement of nonneural cells could lead to SD [8]. It remains to be seen whether receptors other than angiotensin-converting enzyme 2 facilitate entry of SARS-CoV-2 into the host cell and may be involved in the initial infection [11].

Up to 60% of patients with common cold or postviral acute rhinosinusitis may have some degree of SD, this being correlated mainly with disease severity and usually transient (3-7 days) [9]. However, the underlying mechanism through which SARS-CoV-2 virus affects the olfactory system remains unclear [2,3,10]. Although the rate of SD did not exceed 5% in the first studies from China, subsequent international studies on COVID-19 have identified SD as a frequent symptom of the disease (Table 1) [2,4,12-39].

Damage to the olfactory nerve during invasion and multiplication of SARS-CoV-2 may explain the anosmia observed in the early stages of COVID-19 [2,3,7]. Therefore, sudden, severe, and isolated dysfunction (anosmia or ageusia) may be more frequently observed in patients with COVID-19 than in those with other respiratory virus infections [3].

Lack of awareness of SD often entails a significant delay between onset of loss of smell and assessment by a health care professional (HCP) (up to 3 years), despite the considerable effect of this impairment on quality of life [2,32].

In the present study, we report the results of a survey aimed at assessing the impact of STD in HCPs, mainly allergists, with COVID-19. The main objective of the survey was to evaluate the association between STD and its severity and demographic characteristics, symptoms, comorbidities, and hospital admission [33-35].

Methods

Study Population and Design

We designed a 15-item survey to collect the following data: demographics, diagnostic characteristics, STD patterns, symptoms, comorbidities, and medication used (Table 2). The survey was developed using Google forms and based on a collaboration between members of the Spanish ENT Society (SEORL) and the Spanish Society of Allergology and Clinical Immunology (SEAIC). It was distributed to all SEAIC members and disseminated via social media (Twitter, LinkedIn, and Facebook) to be completed by HCPs, mainly allergists, who were affected by COVID-19. Data were collected between May 13 and June 13, 2020. The survey incorporated relevant traits associated with smell and taste. The study was approved by the Institutional Ethics and Clinical Research Committee of Hospital Clinic, Barcelona.

Outcomes

Assessment of smell and taste dysfunction

Participants were asked about timing of onset, duration, and eventual recovery from chemosensory symptoms. The survey included questions associated with STD to determine the following:

- Loss of smell score (Likert scale ranging from 0 to 10, with 0 representing no loss and 10 total loss) focusing on smell and food/drink flavor.
- Loss of taste score (Likert scale ranging from 0 to 10, with 0 representing no loss and 10 total loss). In order to avoid confusion between taste and smell/flavor, real taste perceptions (salty, sweet, bitter, and sour/acidic) were emphasized.
| Author                  | Country                        | N     | Female, % | Mean Age, y | COVID-19–Positive, No. (%) | Study Design   | Effect on Smell and Taste, % | Health Care Professionals, Yes/No |
|-------------------------|--------------------------------|-------|-----------|-------------|---------------------------|----------------|-------------------------------|-----------------------------------|
| Bagheri et al [25]      | Iran                           | 10,069 | 71.1      | 32.5        | -                         | Cross-sectional | SD 87.0                      | No                                |
| Benezit et al [31]      | France                         | 259   | -         | -           | 68 (26.2)                 | Cross-sectional | SD 45.0 TD 62.0               | No                                |
| Giacomelli et al [29]   | Italy                          | 59    | 32.2      | 60.0        | 59 (100)                  | Cross-sectional | STD 33.9 SD+TD 18.6          | No                                |
| Gudbjartsson et al [30] | Iceland                        | 4551  | 47.7      | 40.3        | 528 (11.6)                | Population based | SD 11.5                      | No                                |
| Heidari et al [26]      | Iran                           | 23    | 65.0      | 37.4        | 23 (100)                  | Case-series     | SD 83                        | No                                |
| Izquierdo-Dominguez et al [35] | Spain       | 989   | 47.3      | 56.8        | 846 (85.5)                | Cross-sectional | SD+TD 47.2                  | No                                |
| Kaye et al [17]         | US, Italy, Mexico, UK          | 240   | 54.0      | 39.6        | 237 (98.7)                | Cross-sectional | SD 73.0                      | No                                |
| Klopfenstein et al [13] | France                         | 114   | 67.0      | 47.0        | 54 (47.4)                 | Retrospective observational | SD 47.0 TD 85.0 | No                                |
| Lan et al [20]          | USA                            | 592   | 78.9      | 43.6        | 83 (14.0)                 | Retrospective   | STD 16.0                     | Yes                               |
| Lechien et al [15]      | Belgium, Spain, Italy, France  | 417   | 63.1      | 36.9        | 417 (100)                 | Prospective     | SD 85.0 TD 88.0              | No                                |
| Lechner et al [19]      | UK                             | 3     | 0.0       | 44.3        | 3 (100)                   | Case reports    | SD 100                       | Yes                               |
| Levinson et al [28]     | Israel                         | 45    | 45.2      | 34 (median) | 42 (93.3)                 | Cross-sectional | SD 35.7                     | No                                |
| Mao et al [4]           | China                          | 214   | 59.3      | 52.7        | 214 (100)                 | Observational   | SD 5.1 TD 5.6               | No                                |
| Menni et al [27]        | UK                             | 1702  | 69.0      | 40.8        | 579 (34.0)                | Cross-sectional | SD+TD 59.4                  | No                                |
| Moein et al [18]        | Iran                           | 60    | 33.0      | 46.5        | 60 (100)                  | Case-control    | SD 12.0 TD 7.0 SD+TD 17.0   | No                                |
| Rojas-Lechuga et al [24] | Spain                         | 314   | 63.5      | 46.5        | 197 (62.73)               | Cross-sectional | SD 70.1 TD 65.0 SD+TD 61.9 | No                                |
| Spinato et al [16]      | Italy                          | 202   | 52.0      | 56.0        | 202 (100)                 | Cross-sectional | SD+TD 64.4                  | No                                |
| Van Loon et al [23]     | Belgium                        | 373   | 77.8      | <30-60a     | 185 (49.6)                | Retrospective   | STD 40.0                     | Yes                               |
| Villarreal et al [34]   | Spain                          | 2948  | 85.0      | 43 (median) | 256 (8.7)                 | Observational   | SD 68.0 TD 70.0             | Yes                               |
| Wee et al [14]          | Singapore                      | 870   | -         | -           | 154 (17.7)                | Cross-sectional | SD 22.7                     | No                                |
| Weiss et al [21]        | USA                            | 588   | 79.0      | 37.5        | 17 (3.6)                  | Prospective cohort | SD 53.0                     | Yes                               |
| Yan et al [12]          | USA                            | 1,480 | 49.0      | SbD 18-79   | 102 (6.9)                 | Cross-sectional | SD 68.0 TD 71.0            | No                                |

Abbreviations: SbD, stratified by decade; SD, smell dysfunction; STD, smell and/or taste dysfunction; SD+TD, smell dysfunction and taste dysfunction; TD, taste dysfunction.

*Table modified from Izquierdo-Dominguez et al (J Investig Allergol Clin Immunol 2020; Vol. 30(5): 317-26).
Table 2. Demographics and Clinical Characteristics of the Study Population in Terms of Presence or Absence of Smell and/or Taste Dysfunction

| Population Characteristics | Total (n=234; 100%) | No STD (n=60; 25.6%) | STD (n=174; 74.6%) | P Value |
|-----------------------------|---------------------|----------------------|---------------------|---------|
| Female sex, No. (%)         | 172 (73.5)          | 42 (70.0)            | 130 (74.7)          | .476    |
| Age, y No. (%)              |                     |                      |                     |         |
| 25-35                       | 88 (37.6)           | 27 (45.0)            | 61 (35.1)           |         |
| 36-45                       | 50 (21.4)           | 9 (15.0)             | 41 (23.6)           | .083    |
| 46-55                       | 41 (17.5)           | 10 (16.7)            | 31 (17.8)           |         |
| 56-65                       | 51 (21.8)           | 11 (18.3)            | 40 (23.0)           |         |
| >65                         | 4 (1.7)             | 3 (5.0)              | 1 (0.6)             |         |
| COVID symptoms, No. (%)     |                     |                      |                     |         |
| Cough                       | 145 (62.0)          | 27 (45.0)            | 118 (67.8)          | .002    |
| Headache                    | 142 (60.7)          | 32 (53.3)            | 110 (63.2)          | .176    |
| Asthenia                    | 138 (59.0)          | 35 (58.3)            | 103 (59.2)          | .907    |
| Fever                       | 123 (52.6)          | 27 (45.0)            | 96 (55.2)           | .174    |
| Myalgia                     | 119 (50.9)          | 28 (46.7)            | 91 (52.3)           | .452    |
| Gastrointestinal symptoms   | 111 (47.4)          | 23 (38.3)            | 88 (50.6)           | .102    |
| Tight throat                | 99 (42.9)           | 24 (40.0)            | 75 (43.1)           | .675    |
| Nasal symptoms              | 76 (32.5)           | 10 (16.7)            | 66 (37.9)           | .002    |
| Anorexia                    | 68 (29.1)           | 12 (20.0)            | 56 (32.2)           | .073    |
| Dyspnea                     | 64 (27.4)           | 14 (23.3)            | 50 (28.7)           | .418    |
| Ocular symptoms             | 20 (8.5)            | 4 (6.7)              | 16 (9.2)            | .546    |
| Skin symptoms               | 16 (6.8)            | 3 (5.0)              | 13 (7.5)            | .575    |
| COVID diagnosis, No. (%)    | 175 (74.8)          | 41 (68.3)            | 134 (77.0)          | .248    |
| Positive PCR                | 121 (51.7)          | 24 (40.0)            | 97 (55.7)           | .021    |
| Positive antibody titer     | 94 (40.2)           | 23 (38.3)            | 71 (40.8)           | .148    |
| Hospital admission, No. (%) | 11 (4.7)            | 2 (3.3)              | 9 (5.2)             | .734    |
| Pneumonia, No. (%)          | 24 (10.3)           | 3 (5.0)              | 21 (12.1)           | .120    |
| Comorbidities, No. (%)      |                     |                      |                     |         |
| Smoking habit               | 10 (4.3)            | 4 (6.7)              | 6 (3.4)             | .459    |
| Obesity                     | 30 (12.8)           | 7 (11.7)             | 23 (13.2)           | .757    |
| Hypertension                | 14 (6.0)            | 5 (8.3)              | 9 (5.2)             | .528    |
| Diabetes                    | 4 (1.7)             | 2 (3.3)              | 2 (1.1)             | .575    |
| Allergic rhinitis, No. (%)  | 76 (32.5)           | 26 (43.3)            | 50 (28.7)           | .037    |
| Chronic rhinosinusitis, No. (%) | 14 (6.0)  | 2 (3.3)              | 12 (6.9)            | .371    |
| Asthma, No. (%)             | 32 (13.7)           | 6 (10.0)             | 26 (14.9)           | .337    |
| Severity, No. (%)           |                     |                      |                     | .319    |
| Mild                        | 21 (65.6)           | 5 (83.3)             | 16 (61.5)           |         |
| Moderate                    | 11 (34.4)           | 1 (16.7)             | 10 (38.5)           |         |
| Severe                      | 0                   | 0                    | 0                   |         |
| Treatment, No. (%)          |                     |                      |                     |         |
| Intranasal corticosteroids  | 47 (20.1)           | 14 (23.3)            | 33 (19.0)           | .370    |
| MP-AzeFlu                   | 9 (3.8)             | 4 (6.7)              | 5 (2.9)             | .459    |
| Inhaled corticosteroids     | 37 (15.8)           | 7 (11.7)             | 30 (17.2)           | .355    |
| Immunotherapy               | 10 (4.3)            | 4 (6.7)              | 6 (3.4)             | .459    |
| Biologics                   | 6 (2.6)             | 3 (5.0)              | 3 (1.7)             | .342    |

Abbreviations: MP-AzeFlu, azelastine hydrochloride + fluticasone propionate intranasal formulation; PCR, polymerase chain reaction; STD, smell and/or taste dysfunction.

© 2021 Esmon Publicidad
Table 3. Demographics and Clinical Characteristics of the Study Population in Terms of Presence or Absence of Smell Dysfunction or Taste Dysfunction

| Population Characteristics | Smell Dysfunction | Taste Dysfunction | P Value |
|----------------------------|------------------|------------------|---------|
|                            | No SD (n=74; 31.6%) | SD (n=160; 68.4%) |        |
| Female sex, No. (%)        | 53 (71.6)        | 119 (74.4)       | .657    |
| Age, y, No. (%)            |                 |                  |         |
| 25-35                      | 2 (2.7)          | 12 (7.5)         | .238    |
| 36-45                      | 12 (16.2)        | 38 (23.8)        |        |
| 46-55                      | 15 (20.3)        | 26 (16.3)        | .320    |
| 56-65                      | 15 (20.3)        | 36 (22.5)        | .138    |
| >65                        | 3 (4.1)          | 1 (0.6)          | .007    |
| COVID symptoms, No. (%)    |                 |                  |         |
| Cough                      | 37 (50.0)        | 108 (67.5)       | .010    |
| Headache                   | 42 (56.8)        | 100 (62.5)       |        |
| Asthenia                   | 43 (58.1)        | 95 (59.4)        |        |
| Fever                      | 35 (47.3)        | 88 (55.0)        |        |
| Myalgia                    | 34 (45.9)        | 85 (53.1)        |        |
| Gastrointestinal symptoms  | 33 (44.6)        | 78 (48.8)        |        |
| Tight throat               | 31 (41.9)        | 68 (42.5)        |        |
| Nasal symptoms             | 13 (17.6)        | 63 (39.4)        |        |
| Anorexia                   | 19 (25.7)        | 49 (30.6)        | .438    |
| Dyspnea                    | 19 (25.7)        | 45 (28.1)        |        |
| Ocular symptoms            | 4 (5.4)          | 16 (10.0)        | .242    |
| Skin symptoms              | 4 (5.4)          | 12 (7.5)         |        |
| Mean (SD) TD recovery, days|                 |                  |         |
| Severe (8-10)              | 10.0 ± 8.1       | 3 (2.9)          |         |
| Moderate (4-7)             | 8.3 ± 1.7        | 8.3 ± 1.7        | .094    |
| Mild (0-3)                 | 6.5 ± 0.9        | 9.4 ± 1.4        | .001    |
| COVID diagnosis, No. (%)   | 53 (71.6)        | 122 (76.3)       | .550    |
| Positive PCR               | 29 (39.2)        | 92 (57.5)        | .012    |
| Positive antibody titer    | 29 (39.2)        | 65 (40.6)        | .156    |
| Hospital admission, No. (%)| 4 (5.4)          | 7 (4.4)          | .746    |
| Pneumonia, No. (%)         | 6 (8.1)          | 18 (11.3)        | .461    |
| Smell dysfunction, No. (%)  | 0               | 160 (100)        | .403    |
| Unique symptom, No. (%)    | -               | 12 (7.5)         | .519    |
| Mean (SD) SD score, 0 to 10|                 | 9.1 ± 1.5        | .001    |
| SD severity level, No. (%)  |                | 9.1 ± 1.5        | .001    |
| Mild (0-3)                 | 2 (1.3)          | 0               | 2 (1.7) |
| Moderate (4-7)             | 21 (13.1)        | 14 (33.3)        | 7 (5.9) |
| Severe (8-10)              | 137 (85.6)       | 28 (66.7)        | 109 (92.4) |
| Mean (SD) SD recovery, d   | 26.1 ± 24.7      | 14.6 ± 16.7      | 29.7 ± 25.7 |
| Taste dysfunction, No. (%)  | 14 (18.9)        | 118 (73.8)       | .001    |
| Unique symptom, No. (%)    | 1 (7.1)          | 7 (5.9)          | .128    |
| Mean (SD) TD score, 0 to 10| 5.2 ± 2.8        | 8.3 ± 1.9        | .002    |
| TD severity level, No. (%)  |                 | 7.9 ± 2.3        | .001    |
| Mild (0-3)                 | 5 (38.5)         | 3 (2.6)          | 8 (6.1) |
| Moderate (4-7)             | 5 (38.5)         | 30 (25.6)        | 35 (26.5) |
| Severe (8-10)              | 3 (23.1)         | 84 (71.8)        | 87 (65.9) |
| Mean (SD) TD recovery, days| 10.0 ± 8.1       | 26.2 ± 25.8      | .001    |
| Comorbidities, No. (%)     |                 |                  |         |
| Smoking habit              | 4 (5.4)          | 6 (3.8)          | .560    |
| Obesity                    | 7 (9.5)          | 23 (14.4)        | .296    |
| Hypertension               | 5 (6.8)          | 9 (5.6)          | .770    |
| Diabetes                   | 2 (2.7)          | 2 (1.3)          | .425    |
| Allergic rhinitis, No. (%) | 33 (44.6)        | 43 (26.9)        | .007    |
| Chronic rhinosinusitis, No. (%)| 2 (2.7)       | 12 (7.5)        | .150    |
| Asthma, No. (%)            | 7 (9.5)          | 25 (15.6)        | .202    |
| Severe, No. (%)            |                 |                  | .374    |
| Mild                       | 6 (85.7)         | 15 (60.0)        |        |
| Moderate                   | 6 (85.7)         | 15 (60.0)        |        |
| Severe                     | 0               | 0               |        |
Patients were also asked about their COVID-19 symptoms (fever, rhinitis, conjunctivitis, sore throat, headache, cough, dyspnea, myalgia, asthma, anorexia, gastrointestinal symptoms, and cutaneous symptoms). COVID-19 diagnostic procedures were also recorded (clinical diagnosis, positive result in the polymerase chain reaction [PCR] assay, and antibodies). The comorbidities surveyed were hypertension, diabetes mellitus, obesity, chronic rhinosinusitis, allergic rhinitis, asthma and its severity, and chronic obstructive pulmonary disease. The medications used for respiratory symptoms and comorbidities were also recorded (intranasal corticosteroids, MP-AzeFlu, inhaled corticosteroids, allergen immunotherapy, and biologics) (Tables 3 and 4).

**Statistical Analysis**

With regards to the descriptive analysis, demographic characteristics are expressed as mean (SD). The remaining continuous variables are expressed as median (IQR). Qualitative variables are expressed as absolute frequencies and percentages. The normality of the continuous variables was evaluated using the Shapiro-Wilk test. Statistical significance was set at \( P < .01 \).

The \( \chi^2 \) test and Fisher exact test were used to compare categorical variables between COVID-19 patients with SD, TD, or STD and COVID-19 patients without SD, TD, or STD symptoms. The t test or Mann-Whitney test was used to compare quantitative variables for 2 groups depending on whether or not the variables were normally distributed, whereas analysis of variance and the Kruskal-Wallis test were used for the analysis of quantitative continuous variables for 3 or more groups. The Kruskal-Wallis test was also used to compare ordinal data (eg, severity of SD and TD). We calculated the OR for SD, TD, and STD, with statistical significance set at \( P < .05 \).

Data were analyzed using SPSS Version 20.0 (IBM Corp.). The graphics included in this manuscript were created in Microsoft Excel 2019 (Microsoft).

**Results**

The survey was completed by 234 HCPs (Table 2), of whom 76.5% were aged ≤55 years and 172 were female (73.5%). Demographics and clinical characteristics are detailed in Tables 2-4.

Data on chemosensory dysfunction are shown in Figures 1 and 2.

A total of 174 HCPs (74.6%) reported STD.

**Smell Dysfunction**

A total of 160 HCPs (68.4%) reported SD, which was the only symptom in 7.5% (Figure 1A). Over 85% of participants reported severe smell impairment, with a mean recovery time of 26.1 days. Moreover, HCPs aged >55 years had a slightly better mean score on the SD severity scale (8.49 [1.29]) than HCPs aged ≤55 years (9.29 [2.08]) \((P=.032)\), yet impairment was marked in both age groups. None of the older HCPs reported SD as the only symptom or as the first symptom of COVID-19 (\( P>.004 \)).

Over half of the patients (55.5%) had SD for a median of 4 days after other symptoms, whereas in 30.5% of cases this occurred alongside the other symptoms. Moreover, 24.4% of the HCPs had persistent SD as the only symptom at completion of the survey, and in 9.4% of cases, this was accompanied by other symptoms for a median of 15 days (range, 2-90) (Figure 1A). Among HCPs with COVID-19 and sensory dysfunction, 95.6% experienced at least moderately severe loss of smell (score >5) (Figure 1B). Moreover, the severity of SD was higher in younger HCPs (≤55 years, score 9.3 [1.3], \( P=.04 \)) than in the older group (>55 years, score 8.5 [2.1]).

At completion of the survey, 66.3% of the HCPs had recovered from SD. The dysfunction differed significantly in terms of severity, with the mean time to recovery from SD being 12.5 (3.5) days for mild cases (n=2), 7.1 (3.3) days for moderate cases (n=18), and 29.0 (25.3) days for severe cases \((P<.001)\) (Figure 2A). Moreover, the time to recovery from SD was shorter in younger patients (24.1 [24.1] days vs 31.9 [25.8] days).

**Taste Dysfunction**

A total of 132 HCPs (56.4%) reported TD, which was the only symptom in 6.1% of cases. None of the older HCPs reported TD as the only symptom or as the first symptom of COVID-19 \((P=.047)\). In 6.8% of the respondents, TD preceded...
Table 4. Demographics and Clinical Characteristics of the Study Population Stratified by Age

| Population Characteristics | Age-Stratified Groups | <55 y (n=179) | >55 y (n=55) | P Value |
|----------------------------|-----------------------|---------------|--------------|---------|
| Female sex, No. (%)        |                       | 142 (79.3)    | 30 (54.5)    | .001    |
| COVID symptoms, No. (%)    |                       |               |              |         |
| Cough                      |                       | 106 (59.2)    | 39 (70.9)    | .118    |
| Headache                   |                       | 115 (64.2)    | 27 (49.1)    | .044    |
| Asthenia                   |                       | 105 (58.7)    | 33 (60.0)    | .860    |
| Fever                      |                       | 81 (45.3)     | 42 (76.4)    | .001    |
| Myalgia                    |                       | 86 (48.0)     | 33 (60.0)    | .121    |
| Gastrointestinal symptoms  |                       | 81 (45.3)     | 30 (54.5)    | .227    |
| Tight throat               |                       | 76 (42.5)     | 23 (41.8)    | .993    |
| Nasal symptoms             |                       | 60 (33.5)     | 16 (29.1)    | .540    |
| Anorexia                   |                       | 45 (25.1)     | 23 (41.8)    | .017    |
| Dyspnea                    |                       | 50 (27.5)     | 14 (25.5)    | .718    |
| Ocular symptoms            |                       | 12 (6.7)      | 8 (14.5)     | .095    |
| Skin symptoms              |                       | 13 (7.3)      | 3 (5.5)      | .769    |
| COVID diagnosis, No. (%)   |                       | 125 (69.8)    | 50 (92.6)    | .001    |
| Positive PCR               |                       | 89 (49.7)     | 32 (58.2)    | .390    |
| Antibodies, positivity     |                       | 70 (39.1)     | 24 (43.6)    | .511    |
| Hospital admission, No. (%)|                       | 6 (3.4)       | 5 (9.1)      | .136    |
| Pneumonia, No. (%)         |                       | 15 (8.4)      | 9 (16.4)     | .088    |
| Smell dysfunction, No. (%) |                       | 123 (68.7)    | 37 (67.3)    | .841    |
| Unique symptom, No. (%)    |                       | 12 (9.5)      | 0            | .074    |
| Mean (SD) SD score, 0 to 10|                       | 9.3 ± 1.3     | 8.5 ± 2.1    | .040    |
| SD severity level, No. (%) |                       | Mild (0-3)    | 0            | .54 (5.4) |
|                           |                       | Moderate (4-7)| 15 (12.2)    | 6 (16.2) |
|                           |                       | Severe (8-10) | 108 (87.8)   | 29 (78.4) |
| Mean (SD) SD recovery, days |                   | 24.1 ± 24.1   | 13.1 ± 25.8  | .099    |
| Taste dysfunction, No. (%) |                       | 102 (57.0)    | 30 (54.5)    | .750    |
| Unique symptom, No. (%)    |                       | 8 (7.2)       | 0            | .203    |
| Mean (SD) TD score, 0 to 10|                       | 8.0 ± 2.1     | 7.8 ± 2.6    | .566    |
| TD severity level, No. (%) |                       | Mild (0-3)    | 4 (4.0)      | 4 (13.8) |
|                           |                       | Moderate (4-7)| 28 (27.7)    | 7 (24.1) |
|                           |                       | Severe (8-10) | 69 (68.3)    | 18 (61.1) |
| Mean (SD) TD recovery, days |                   | 21.6 ± 24.0   | 33.6 ± 26.2  | .019    |
| Comorbidities, No. (%)     |                       |               |              |         |
| Smoking habit              |                       | 6 (3.4)       | 4 (7.3)      | .251    |
| Obesity                    |                       | 17 (9.5)      | 13 (23.6)    | .006    |
| Hypertension               |                       | 2 (1.1)       | 12 (21.8)    | .001    |
| Diabetes                   |                       | 0             | 4 (7.3)      | .003    |
| Allergic rhinitis, No. (%) |                       | 72 (40.2)     | 4 (7.3)      | .001    |
| Chronic rhinosinusitis, No.|                       | 8 (4.5)       | 6 (10.9)     | .101    |
| Asthma, No. (%)            |                       | 30 (16.8)     | 2 (3.6)      | .013    |
| Severity, No. (%)          |                       | Mild          | 21 (70.0)    | 0       |
|                           |                       | Moderate      | 9 (30.0)     | 2 (100) |
|                           |                       | Severe        | 0            | 0       |
| Treatment, No. (%)         |                       |               |              |         |
| Intranasal corticosteroids |                       | 41 (22.9)     | 6 (10.9)     | .052    |
| MP-AzeFlu                  |                       | 8 (4.5)       | 1 (1.8)      | .467    |
| Inhaled corticosteroids    |                       | 33 (18.4)     | 4 (7.3)      | .047    |
| Immunotherapy              |                       | 9 (5.0)       | 1 (1.8)      | .459    |
| Biologics                  |                       | 5 (2.8)       | 1 (1.8)      | .689    |

Abbreviations: MP-AzeFlu, azelastine hydrochloride + fluticasone propionate intranasal formulation; PCR, polymerase chain reaction; SD, smell dysfunction; TD, taste dysfunction.

Figure 1. Frequency and severity distribution of smell and taste dysfunction in the COVID-19 HCP population. A, Frequency of smell and taste dysfunction overall (black bars), according to accompanying symptoms (dark gray bars), and as the only symptom (light gray bars). B, Severity of smell and taste dysfunction for either mild (light gray bars), moderate (dark gray bars), or severe dysfunction (black bars).
Discussion

Participants diagnosed with COVID-19 were HCPs (mainly female). STD was observed in 118 participants (67.8% of the total population surveyed). In recent reports, the authors mainly assess these 2 chemosensory dysfunctions separately. Menni et al [27] reported SD and TD in 59.4% of their study population, whereas Spinato et al [16] found this figure to be 64.4%; both figures are slightly lower than those we report. Wee et al [14] found that only 22.7% of the population studied had both SD and TD, and, in Iran, Moein et al [18] reported that only 17% of their population had both chemosensory dysfunctions. These differences could be explained by the fact that our population was composed mainly of HCPs, most of whom were female, thus potentially constituting a bias, and, as previously published, females with COVID-19 may be at higher risk of developing SD [15,20,21,23,25-26]. In a recent study published in Spain, a total of 157/230 HCPs (68%) reported SD and 161/230 (70%) reported TD, with a similar prevalence independently of age or sex [34]. In contrast, in our sample, females were significantly more affected than males in terms of STD, as shown in a study based on big data in Spain [37].

Data on STD and sex predominance are contradictory. A recent meta-analysis found no significant moderation of the prevalence of STD by sex [22]. In contrast, consistent with our results, a multicenter European study found that females were significantly more affected by STD than males [15]. Similarly, in another study performed in Spain, mostly females and younger people were affected by STD [35]. In our study, the frequencies of loss of smell (68.4%) and taste (56.4%) were higher than those reported in the early observational studies from China [4], Iceland [30], and, more recently, Belgium, United Kingdom, and Spain [2,15,23,35], although lower than those from the aforementioned European multicenter study [15].

Participating HCPs who experienced SD were younger than those not affected with STD, as 70% of the COVID-19–positive population were aged ≤55 years, with this figure being higher than that reported in a recent Korean study, where only 15.3% of the total COVID-19 population had STD, and even much higher than in other studies of HCPs, with a range of 16%-40% [32]. Our percentages are slightly higher than those of other authors in Spain, who reported SD in 68% of patients and TD in 70% [2,24]. We hypothesize that these differences could be due to awareness of STD among HCPs and its relationship with COVID-19. In a Swedish population, individuals progressing from no symptoms to subsequently complaining of COVID-19 symptoms reported a large drop in olfactory performance [38], suggesting that measures of odor intensity, if obtained in a large and representative sample, could be used as an indicator of SARS-CoV-2 infection in the general population [39]. Foster et al [36] recently published that SD could be a prognostic factor for lower severity of COVID-19. This observation is in line with findings from China, which show that the ratio of hospitalized patients complaining of loss of smell and taste was only 5.1% and 5.6%, respectively [4]. Our results do not show any association between SD and the severity of COVID-19. HCPs who reported TD, however, were more frequently admitted to hospital.

We aimed to investigate whether age (≤ or >55 years) was associated with the presence of SD as the only symptom or as the first symptom of COVID-19. Interestingly, none of the older HCPs reported having SD as the only symptom or as the first symptom of COVID-19. Similar findings were obtained for TD.

Our finding that SD was the only symptom was less frequent than that obtained elsewhere in Spain, with percentages ranging from 18.9% to 21.8% [2]. These results also contrast with another study, in which STD persisted on average 11 days [34].

Our study also reflects persistence of SD, which is on average longer than observed in other publications [1,34,35]. We presume that the viral load in the clinical setting could explain this longer time to recovery. In a study that recruited HCPs in Spain, most of the affected individuals recovered both smell and taste in the first 15 days, and up to 26% of
the HCPs affected had persistent anosmia 1 month after onset [34].

In a Korean study, most of the COVID-19 patients with loss of smell and/or taste recovered within 3 weeks, consistent with our results [32]. The median time to recovery was 7 days for both symptoms. Anosmia tended to persist for longer in younger persons, particularly those aged 20-39 years. Our results indicate that younger individuals take longer to recover from SD, although this observation could be subject to bias, because over 70% of the HCPs surveyed were aged ≤55 years. Reflecting our results, the mean recovery time from loss/distortion of taste was similar to that from the loss of smell [32].

Loss of smell appeared before the other COVID-19 symptoms, albeit less frequently than reported in previous studies, but persisted up to 90 days. In 6.9% of the HCPs included in our study, this loss of smell preceded the other COVID-19 symptoms (median of 3 days). In a recent study of 417 patients with mild-to-moderate COVID-19, SD appeared before the other symptoms in 11.8% of cases, a slightly higher proportion than in our study [15]. In another recently published Spanish study, only 1.3% of the HCPs had SD as their only symptom [34].

Over half of the HCPs surveyed presented SD, TD, or STD, with a severity that was similar to that reported in previous studies [2,35]. We hypothesize that this finding was the result of potentially greater and sustained exposure to the SARS-CoV-2 viral load within the clinical setting, along with more marked impairment of quality of life in HCPs ≤55 years. In this sense, a recent meta-analysis reported a prevalence of TD ranging from 5.6% to 62.7%, with the pooled prevalence (38.2%) clearly lower than that we reported. The authors of the meta-analysis state that the pooled prevalence tended to decrease with increasing mean age and was slightly higher across European studies than in studies from elsewhere [22].

No significant association was found between SD and smoking. Previous non-COVID studies report negative and positive effects of smoking on SD of different causes [39]. However, smoking cessation seems to improve both rated and measured smell function. Only 4.3% of our sample were smokers, which seems to be clearly lower than in the general population. In addition, our population comprised mainly HCPs, who tend to smoke less than the general population. Notwithstanding, in a recent study of 3900 patients with loss of smell, 521 were current smokers and 316 former smokers. The authors concluded that patients with a history of smoking did not have a significantly diminished smell function [40]. Given that our sample of smokers is quite small, the results regarding the absence of an association between SD and smoking should be interpreted with caution.

Older age (>55 years) was significantly associated with fever and anorexia, but less with headache and COVID-19 positivity. These results are in line with a big data–based analysis in Spain, which revealed an age-dependent increase in reported cases (both males and females), with patients >79 years being the most affected [37]. Regarding symptoms at diagnosis, headache, anosmia, and taste distortion were significantly more frequent in women than in men in the above-mentioned analysis. In our population, headache was reported less frequently by older patients. A study of 989 individuals in Spain revealed a clear association between loss of smell and taste in persons aged <60 years and nonhospitalized patients [35].

TD was more frequent in HCPs who had COVID-19 with pneumonia, a finding that differs from those reported elsewhere. Nevertheless, there were no significant differences in smell or taste with regards to sex, age range, or frequency of pneumonia, consistent with the results of another study performed in HCPs in Spain [34].

Consistent with the data reported by Villarreal et al [34], where cough was one of the main symptoms in HCPs with COVID-19, we found cough to be significantly associated with SD and STD.

One of the limitations of the study is that a definitive diagnosis was reached by means of PCR and/or antibody titers in 161 of the 234 respondents. Since our survey aimed to assess only COVID-19 patients, we presumed that the remaining participants had a clinical diagnosis of COVID-19, although we did not confirm this association. However, in the HCPs surveyed in our sample, TD seemed to be a prognostic marker of the severity of COVID-19. Moreover, given the recruitment period, the first stage of the survey could be affected by bias, because PCR and SARS-CoV-2 antibody assays were not fully available in all centers in the midst of the SARS-CoV-2 outbreak; therefore, this could constitute a limitation of the study. Furthermore, the sample may not be representative of the general population as it included HCPs, although it could be representative of the specific population being analyzed, namely HCPs, most of whom were allergists and women. Notwithstanding, this potential limitation is also a strength, as it is the first assessment to date of STD in allergists with COVID-19.

In summary, ST and TD were frequent in HCPs (mainly allergists) with COVID-19, affecting 68.4% and 56.4% of the study population, respectively. Stratified analysis by severity of STD showed that more than half of HCPs with COVID-19 presented severe loss of smell. Older HCPs seem to experience STD at the same time as other COVID-19 symptoms, in contrast with younger HCPs, who had STD as the only or a preceding symptom. TD may be considered a prognostic clinical marker of the severity of COVID-19, since having TD may also imply more systemic involvement. Further studies will be needed to explain these chemosensory impairments, as well as the pathogenic mechanisms underlying loss of smell and loss of taste. Finally, the assessment of STD (both SD and TD) is of significant importance in COVID-19 patients, including HCPs, at any stage of the disease. Patients with sudden, severe, and isolated symptoms (SD and/or TD) should self-isolate while waiting for a diagnostic PCR test, when available.

Funding

The authors declare that no funding was received for the present study.

Conflicts of Interest

Dr Antolín Amérgo reports having received lecture fees from Mylan-MEDA Pharma, AstraZeneca, FAES Farma, Leti,
GSK, as well as advisory fees from Chiesi, and Sanofi outside the submitted work.

Dr Carlos Colás reports having served as a consultant to Mylan and AstraZeneca and having been paid lecture fees by AstraZeneca, GSK, Mylan, and MSD. He has also received grants from Roxall, Novartis, AstraZeneca, and Sanofi.

Dr Alobid reports personal fees from Menarini, GSK, Sanofi, and Novartis during the conduct of the study.

Dr Mullol reports personal and other fees from Sanofi-Genzyme, Regeneron, Novartis, and Allakos and grants and personal fees from Mylan-MEDA Pharma, and Uricia Group. He also reports personal fees from MITSUBISHI-TANABE, Menarini, UCB, AstraZeneca, GSK, and MSD outside the submitted work.

The remaining authors declare that they have no conflicts of interest.

References

1. Lee S, Persson P. Financing from family and friends. Rev Financ Stud. 2016;29(9):2341-86.
2. Izquierdo-Domínguez A, Rojas-Lechuga M, Mullol J, Alobid I. Olfactory dysfunction in the COVID-19 outbreak. J Investig Allergol Clin Immunol. 2020;30(5):317-26.
3. Mullol J, Alobid I, Marín-Sánchez F, Izquierdo-Domínguez A, Marín C, Klimek L, et al. The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. Curr Allergy Asthma Rep. 2020;20(10):61.
4. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-90.
5. Pang KW, Chee J, Subramaniam S, Ng CL. Frequency and Clinical Utility of Olfactory Dysfunction in COVID-19: a Systematic Review and Meta-analysis. Curr Allergy Asthma Rep. 2020;20(12):76.
6. Liu DT, Besser G, Renner B, Seyferth S, Hummel T, Mueller CA. Retronasal olfactory function in patients with smell loss but subjectively normal flavor perception. Laryngoscope. 2020;130(7):1629-33.
7. Mullol J, Alobid I, Marín-Sánchez F, Quinto L, de Haro J, Bernal-Sprekelsen M, et al. Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACT study). BMJ Open. 2012;2(6):e001256.
8. Brann D, Tsukahara T, Weinreb C, Logan DW, Datta SR. Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients. bioRxiv. 2020;2020.03.25.009084.
9. Jaume F, Quinto L, Alobid I, Mullol J. Overuse of diagnostic tools and medications in acute rhinosinusitis in Spain: A population-based study (the PROSINUS study). BMJ Open. 2018;8(1):1-13.
10. Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age. ACS Chem Neurosci. 2020;11(11):1555-62.
Manuscript received October 9, 2020; accepted for publication January 19, 2021.

Darío Antolín Amérgio

Hospital Universitario Ramón y Cajal
M-607, km. 9,100
28034 Madrid, Spain
E-mail: dario.antolin@seaic.org

Joaquim Mullol i Miret
Hospital Clinic Barcelona - IDIBAPS
E-mail: jmullol@clinic.cat